Moleculin Biotech, Inc. (MBRX) SEC filings

MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30

$7.87−0.19 (-2.36%)

Close on Nov 13, 2026Market cap $8.23MP/E –Yield –

SEC filings

40 of Moleculin Biotech's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 13, 2026	SEC EDGAR
Current report	8-K	Nov 12, 2026	Nov 12, 2026	SEC EDGAR
Current report	8-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Current report	8-K	Nov 4, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Oct 30, 2026	Oct 30, 2026	SEC EDGAR
Current report	8-K	Oct 16, 2026	Oct 20, 2026	SEC EDGAR
Current report	8-K	Oct 16, 2026	Oct 16, 2026	SEC EDGAR
Current report	8-K	Oct 9, 2026	Oct 9, 2026	SEC EDGAR
Current report	8-K	Oct 5, 2026	Oct 5, 2026	SEC EDGAR
Current report	8-K	Sep 29, 2026	Sep 29, 2026	SEC EDGAR
Current report	8-K	Sep 28, 2026	Sep 28, 2026	SEC EDGAR
Current report	8-K	Sep 25, 2026	Sep 25, 2026	SEC EDGAR
Current report	8-K	Sep 23, 2026	Sep 23, 2026	SEC EDGAR
Current report	8-K	Sep 15, 2026	Sep 18, 2026	SEC EDGAR
Current report	8-K	Sep 14, 2026	Sep 14, 2026	SEC EDGAR
Current report	8-K	Aug 31, 2026	Aug 31, 2026	SEC EDGAR
Proxy statement	DEF 14A	Oct 9, 2026	Aug 24, 2026	SEC EDGAR
Current report	8-K	Aug 14, 2026	Aug 14, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Jul 31, 2026	Aug 3, 2026	SEC EDGAR
Current report	8-K	Jul 31, 2026	Jul 31, 2026	SEC EDGAR
Current report	8-K	Jun 30, 2026	Jun 30, 2026	SEC EDGAR
Current report	8-K	Jun 30, 2026	Jun 30, 2026	SEC EDGAR
Current report	8-K	Jun 5, 2026	Jun 5, 2026	SEC EDGAR
Current report	8-K	May 29, 2026	May 29, 2026	SEC EDGAR
Current report	8-K	May 26, 2026	May 26, 2026	SEC EDGAR
Current report	8-K	May 22, 2026	May 22, 2026	SEC EDGAR
Current report	8-K	May 15, 2026	May 15, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 14, 2026	SEC EDGAR
Current report	8-K	May 13, 2026	May 13, 2026	SEC EDGAR
Current report	8-K	May 12, 2026	May 12, 2026	SEC EDGAR
Current report	8-K	May 8, 2026	May 8, 2026	SEC EDGAR
Current report	8-K	Apr 23, 2026	Apr 23, 2026	SEC EDGAR
Current report	8-K	Apr 15, 2026	Apr 15, 2026	SEC EDGAR
Annual report, amended	10-K/A	Dec 31, 2025	Apr 14, 2026	SEC EDGAR
Current report	8-K	Mar 23, 2026	Mar 23, 2026	SEC EDGAR
Current report	8-K	Mar 19, 2026	Mar 19, 2026	SEC EDGAR
Current report	8-K	Mar 19, 2026	Mar 19, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 18, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 15, 2026	Mar 9, 2026	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Moleculin Biotech's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Oct 20, 2026
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MBRX.

Compare: MBRX vs SLS · MBRX vs PYXS · MBRX vs CLRB · MBRX vs KZIA · MBRX vs RNAZ

Company	Revenue	Growth
MBRX	$0	–
SLS	–	–
PYXS	–	–
CLRB	–	–
KZIA	–	–
RNAZ	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 150,000
Held by institutions: 0.0%
Auditor: GRANT THORNTON LLP
SEC CIK: 1659617

Advertisement
300 × 250

See a number that looks wrong?